1. Home
  2. GMAB vs GGG Comparison

GMAB vs GGG Comparison

Compare GMAB & GGG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$27.94

Market Cap

16.9B

Sector

Health Care

ML Signal

HOLD

Logo Graco Inc.

GGG

Graco Inc.

HOLD

Current Price

$86.92

Market Cap

14.7B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
GMAB
GGG
Founded
1999
1926
Country
Denmark
United States
Employees
3029
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Fluid Controls
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
16.9B
14.7B
IPO Year
N/A
1994

Fundamental Metrics

Financial Performance
Metric
GMAB
GGG
Price
$27.94
$86.92
Analyst Decision
Strong Buy
Buy
Analyst Count
8
4
Target Price
$39.81
$95.25
AVG Volume (30 Days)
1.5M
861.4K
Earning Date
05-07-2026
04-22-2026
Dividend Yield
N/A
1.36%
EPS Growth
N/A
9.22
EPS
N/A
3.08
Revenue
N/A
$2,236,604,000.00
Revenue This Year
$17.85
$6.77
Revenue Next Year
$16.04
$4.86
P/E Ratio
$1.90
$28.18
Revenue Growth
N/A
5.83
52 Week Low
$18.89
$77.19
52 Week High
$35.43
$95.69

Technical Indicators

Market Signals
Indicator
GMAB
GGG
Relative Strength Index (RSI) 50.65 50.19
Support Level $24.95 $81.15
Resistance Level $29.86 $88.15
Average True Range (ATR) 0.60 1.84
MACD 0.18 0.24
Stochastic Oscillator 54.42 59.83

Price Performance

Historical Comparison
GMAB
GGG

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

About GGG Graco Inc.

Graco manufactures equipment used for managing fluids, coatings, and adhesives, specializing in difficult-to-handle materials. Graco's business is organized into three segments: industrial, process, and contractor. The Minnesota-based firm serves a wide range of end markets, including industrial, automotive, and construction, and its broad array of products include pumps, valves, meters, sprayers, and equipment used to apply coatings, sealants, and adhesives. The firm generated roughly $2.2 billion in sales in 2025.

Share on Social Networks: